Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

Cell

Volumn 174, Issue 4, 2018, Pages 938-952.e13

  Saphire, Erica Ollmann ^a   Schendel, Sharon L ^a   Fusco, Marnie L ^a   Gangavarapu, Karthik ^a   Gunn, Bronwyn M ^b   Wec, Anna Z ^c   Halfmann, Peter J ^d   Brannan, Jennifer M ^e   Herbert, Andrew S ^e   Qiu, Xiangguo ^f   Wagh, Kshitij ^g   He, Shihua ^f   Giorgi, Elena E ^g   Theiler, James ^g   Pommert, Kathleen B J ^a   Krause, Tyler B ^c   Turner, Hannah L ^a   Murin, Charles D ^a   Pallesen, Jesper ^a   Davidson, Edgar ^h   Ahmed, Rafi ⁱ   Aman, M Javad ^j   Bukreyev, Alexander ^k   Burton, Dennis R ^a   Crowe, James E ^l   Davis, Carl W ⁱ   Georgiou, George ^m   Krammer, Florian ⁿ   Kyratsous, Christos A ^o   Lai, Jonathan R ^c   Nykiforuk, Cory ^p   Pauly, Michael H ^q   Rijal, Pramila ^r   Takada, Ayato ^s   Townsend, Alain R ^r   Volchkov, Viktor ^t   Walker, Laura M ^u   Wang, Cheng I ^v   Zeitlin, Larry ^q   Doranz, Benjamin J ^h   Ward, Andrew B ^a   Korber, Bette ^g   Kobinger, Gary P ^w   Andersen, Kristian G ^a   Kawaoka, Yoshihiro ^d   Alter, Galit ^b   Chandran, Kartik ^c   Dye, John M ^e   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Koch Institute for Integrative Cancer Research   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e U S ARMY   (United States)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^g LOS ALAMOS NATIONAL LABORATORY   (United States)

^h Integral Molecular Inc   (United States)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Integrated BioTherapeutics   (United States)

^k UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^m The University of Texas at Austin   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o REGENERON PHARMACEUTICALS INC   (United States)

^p Emergent Biosolutions   (Canada)

^q Mapp Biopharmaceutical   (United States)

^r UNIVERSITY OF OXFORD   (United Kingdom)

^s HOKKAIDO UNIVERSITY   (Japan)

^t UNIVERSITÉ DE LYON   (France)

^u Adimab LLC   (United States)

^v AGENCY FOR SCIENCE   (Singapore)

^w UNIVERSITÉ LAVAL   (Canada)

more..

Author keywords

antibody; consortium; ebola virus; epitope; glycoprotein; neutralization; protection

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN; EPITOPE; MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; ENDOSOME; EPITOPE MAPPING; FEMALE; FILOVIRUS; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MACHINE LEARNING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTOSIS; PREDICTION; PRIORITY JOURNAL; VIRION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; TREATMENT OUTCOME; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; EBOLAVIRUS; EPITOPES; FEMALE; HEMORRHAGIC FEVER, EBOLA; IMMUNIZATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 85050869127     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.07.033     Document Type: Article

References (85)

1. Ackerman, M.E., Mikhailova, A., Brown, E.P., Dowell, K.G., Walker, B.D., Bailey-Kellogg, C., Suscovich, T.J., Alter, G., Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. PLoS Pathog., 12, 2016, e1005315.
2. Alter, G., Malenfant, J.M., Altfeld, M., CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294 (2004), 15–22.
3. Audet, J., Wong, G., Wang, H., Lu, G., Gao, G.F., Kobinger, G., Qiu, X., Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci. Rep., 4, 2014, 6881.
4. Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T.H., Britt, W.J., Mach, M., Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog., 13, 2017, e1006601.
5. Bornholdt, Z.A., Turner, H.L., Murin, C.D., Li, W., Sok, D., Souders, C.A., Piper, A.E., Goff, A., Shamblin, J.D., Wollen, S.E., et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351 (2016), 1078–1083.
6. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., Huggins, J., A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178 (1998), 651–661.
7. Breiman, L., Random Forests. Mach. Learn. 45 (2001), 5–32.
8. Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (2012), 5640–5649.
9. Chandran, K., Sullivan, N.J., Felbor, U., Whelan, S.P., Cunningham, J.M., Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308 (2005), 1643–1645.
10. Chung, A.W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M.K., Rolland, M., Suscovich, T.J., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med., 6, 2014, 228ra38.
11. Corey, L., Gilbert, P.B., Tomaras, G.D., Haynes, B.F., Pantaleo, G., Fauci, A.S., Immune correlates of vaccine protection against HIV-1 acquisition. Sci. Transl. Med., 7, 2015, 310rv7.
12. Corti, D., Misasi, J., Mulangu, S., Stanley, D.A., Kanekiyo, M., Wollen, S., Ploquin, A., Doria-Rose, N.A., Staupe, R.P., Bailey, M., et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351 (2016), 1339–1342.
13. Davidson, E., Bryan, C., Fong, R.H., Barnes, T., Pfaff, J.M., Mabila, M., Rucker, J.B., Doranz, B.J., Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. J. Virol. 89 (2015), 10982–10992.
14. Dias, J.M., Kuehne, A.I., Abelson, D.M., Bale, S., Wong, A.C., Halfmann, P., Muhammad, M.A., Fusco, M.L., Zak, S.E., Kang, E., et al. A shared structural solution for neutralizing ebolaviruses. Nat. Struct. Mol. Biol. 18 (2011), 1424–1427.
15. Dube, D., Brecher, M.B., Delos, S.E., Rose, S.C., Park, E.W., Schornberg, K.L., Kuhn, J.H., White, J.M., The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 83 (2009), 2883–2891.
16. Ebihara, H., Takada, A., Kobasa, D., Jones, S., Neumann, G., Theriault, S., Bray, M., Feldmann, H., Kawaoka, Y., Molecular determinants of Ebola virus virulence in mice. PLoS Pathog., 2, 2006 e73–e73.
17. Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E.B., Payne, R., Fehling, S.K., Strecker, T., et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N. Engl. J. Med. 374 (2016), 1635–1646.
18. Flyak, A.I., Ilinykh, P.A., Murin, C.D., Garron, T., Shen, X., Fusco, M.L., Hashiguchi, T., Bornholdt, Z.A., Slaughter, J.C., Sapparapu, G., et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160 (2015), 893–903.
19. Flyak, A.I., Shen, X., Murin, C.D., Turner, H.L., David, J.A., Fusco, M.L., Lampley, R., Kose, N., Ilinykh, P.A., Kuzmina, N., et al. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell 164 (2016), 392–405.
20. Fusco, M.L., Hashiguchi, T., Cassan, R., Biggins, J.E., Murin, C.D., Warfield, K.L., Li, S., Holtsberg, F.W., Shulenin, S., Vu, H., et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog., 11, 2015, e1005016.
21. Geurts, P., Ernst, D., Wehenkel, L., Extremely randomized trees. Mach. Learn. 63 (2006), 3–42.
22. Gibb, T.R., Bray, M., Geisbert, T.W., Steele, K.E., Kell, W.M., Davis, K.J., Jaax, N.K., Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125 (2001), 233–242.
23. Goh, A.X.H., Bertin-Maghit, S., Ping Yeo, S., Ho, A.W.S., Derks, H., Mortellaro, A., Wang, C.-I., A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy. MAbs 6 (2014), 765–773.
24. Gunn, B.M., Yu, W.-H., Karim, M.M., Brannan, J., Wec, A.Z., Fusco, M.L., Schendel, S.L., Gangavarapu, K., Das, J., Suscovich, T., et al. Dissecting the role of Fc and Fab mediated functions in Ebola virus specific immunity. Cell Host Microbe, 2018, 10.1016/j.chom.2018.07.015.
25. Halfmann, P., Kim, J.H., Ebihara, H., Noda, T., Neumann, G., Feldmann, H., Kawaoka, Y., Generation of biologically contained Ebola viruses. Proc. Natl. Acad. Sci. USA 105 (2008), 1129–1133.
26. Hasegawa, H., van Reit, E., Kida, H., Mucosal immunization and adjuvants. Curr. Top. Microbiol. Immunol. 386 (2015), 371–380.
27. Hashiguchi, T., Fusco, M.L., Bornholdt, Z.A., Lee, J.E., Flyak, A.I., Matsuoka, R., Kohda, D., Yanagi, Y., Hammel, M., Crowe, J.E. Jr., Saphire, E.O., Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160 (2015), 904–912.
28. Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M., Evans, D.T., Montefiori, D.C., Karnasuta, C., Sutthent, R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366 (2012), 1275–1286.
29. Henry Dunand, C.J., Leon, P.E., Huang, M., Choi, A., Chromikova, V., Ho, I.Y., Tan, G.S., Cruz, J., Hirsh, A., Zheng, N.-Y., et al. Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection. Cell Host Microbe 19 (2016), 800–813.
30. Holtsberg, F.W., Shulenin, S., Vu, H., Howell, K.A., Patel, S.J., Gunn, B., Karim, M., Lai, J.R., Frei, J.C., Nyakatura, E.K., et al. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses. J. Virol. 90 (2015), 266–278.
31. Horwitz, J.A., Bar-On, Y., Lu, C.-L., Fera, D., Lockhart, A.A.K., Lorenzi, J.C.C., Nogueira, L., Golijanin, J., Scheid, J.F., Seaman, M.S., et al. Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. Cell 170 (2017), 637–648.e10.
32. Huang, K.-Y.A., Rijal, P., Schimanski, L., Powell, T.J., Lin, T.-Y., McCauley, J.W., Daniels, R.S., Townsend, A.R., Focused antibody response to influenza linked to antigenic drift. J. Clin. Invest. 125 (2015), 2631–2645.
33. Ilinykh, P.A., Shen, X., Flyak, A.I., Kuzmina, N., Ksiazek, T.G., Crowe, J.E. Jr., Bukreyev, A., Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. J. Virol. 90 (2016), 3890–3901.
34. Keck, Z.-Y., Enterlein, S.G., Howell, K.A., Vu, H., Shulenin, S., Warfield, K.L., Froude, J.W., Araghi, N., Douglas, R., Biggins, J., et al. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein. J. Virol. 90 (2015), 279–291.
35. Khurana, S., Fuentes, S., Coyle, E.M., Ravichandran, S., Davey, R.T. Jr., Beigel, J.H., Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat. Med. 22 (2016), 1439–1447.
36. Koellhoffer, J.F., Chen, G., Sandesara, R.G., Bale, S., Saphire, E.O., Chandran, K., Sidhu, S.S., Lai, J.R., Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein. ChemBioChem 13 (2012), 2549–2557.
37. Krammer, F., Palese, P., Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14 (2015), 167–182.
38. Lee, J.E., Fusco, M.L., Hessell, A.J., Oswald, W.B., Burton, D.R., Saphire, E.O., Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454 (2008), 177–182.
39. Lennemann, N.J., Herbert, A.S., Brouillette, R., Rhein, B., Bakken, R.A., Perschbacher, K.J., Cooney, A.L., Miller-Hunt, C.L., Ten Eyck, P., Biggins, J., et al. Vesicular stomatitis virus pseudotyped with Ebola virus glycoprotein serves as a protective, non-infectious vaccine against Ebola virus challenge in mice. J. Virol., 91, 2017 e00479-17.
40. Lewis, G.K., Finzi, A., DeVico, A.L., Pazgier, M., Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. Viruses 7 (2015), 5115–5132.
41. Lewis, G.K., Pazgier, M., Evans, D.T., Ferrari, G., Bournazos, S., Parsons, M.S., Bernard, N.F., Finzi, A., Beyond Viral Neutralization. AIDS Res. Hum. Retroviruses 33 (2017), 760–764.
42. Li, D., Chen, T., Hu, Y., Zhou, Y., Liu, Q., Zhou, D., Jin, X., Huang, Z., An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. J. Virol. 90 (2016), 8720–8728.
43. Lux, A., Yu, X., Scanlan, C.N., Nimmerjahn, F., Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 190 (2013), 4315–4323.
44. Macdonald, L.E., Karow, M., Stevens, S., Auerbach, W., Poueymirou, W.T., Yasenchak, J., Frendewey, D., Valenzuela, D.M., Giallourakis, C.C., Alt, F.W., et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc. Natl. Acad. Sci. USA 111 (2014), 5147–5152.
45. Mahan, A.E., Tedesco, J., Dionne, K., Baruah, K., Cheng, H.D., De Jager, P.L., Barouch, D.H., Suscovich, T., Ackerman, M., Crispin, M., Alter, G., A method for high-throughput, sensitive analysis of IgG Fc and Fab glycosylation by capillary electrophoresis. J. Immunol. Methods 417 (2015), 34–44.
46. Maruyama, T., Rodriguez, L.L., Jahrling, P.B., Sanchez, A., Khan, A.S., Nichol, S.T., Peters, C.J., Parren, P.W., Burton, D.R., Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73 (1999), 6024–6030.
47. Marzi, A., Yoshida, R., Miyamoto, H., Ishijima, M., Suzuki, Y., Higuchi, M., Matsuyama, Y., Igarashi, M., Nakayama, E., Kuroda, M., et al. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE, 7, 2012, e36192.
48. Mayr, L.M., Decoville, T., Schmidt, S., Laumond, G., Klingler, J., Ducloy, C., Bahram, S., Zolla-Pazner, S., Moog, C., Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. Sci. Rep., 7, 2017, 12655.
49. Miller, E.H., Obernosterer, G., Raaben, M., Herbert, A.S., Deffieu, M.S., Krishnan, A., Ndungo, E., Sandesara, R.G., Carette, J.E., Kuehne, A.I., et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 31 (2012), 1947–1960.
50. Mohan, G.S., Li, W., Ye, L., Compans, R.W., Yang, C., Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog., 8, 2012, e1003065.
51. Murin, C.D., Fusco, M.L., Bornholdt, Z.A., Qiu, X., Olinger, G.G., Zeitlin, L., Kobinger, G.P., Ward, A.B., Saphire, E.O., Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci. USA 111 (2014), 17182–17187.
52. Murphy, A.J., Macdonald, L.E., Stevens, S., Karow, M., Dore, A.T., Pobursky, K., Huang, T.T., Poueymirou, W.T., Esau, L., Meola, M., et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl. Acad. Sci. USA 111 (2014), 5153–5158.
53. Olinger, G.G. Jr., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S.D., Johnson, A.K., Morton, J., et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109 (2012), 18030–18035.
54. Oliva, A., Kinter, A.L., Vaccarezza, M., Rubbert, A., Catanzaro, A., Moir, S., Monaco, J., Ehler, L., Mizell, S., Jackson, R., et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J. Clin. Invest. 102 (1998), 223–231.
55. Oswald, W.B., Geisbert, T.W., Davis, K.J., Geisbert, J.B., Sullivan, N.J., Jahrling, P.B., Parren, P.W.H.I., Burton, D.R., Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog., 3, 2007, e9.
56. Pascal, K.E., Dudgeon, D., Trefry, J.C., Anantpadma, M., Sakurai, Y., Murin, C.D., Turner, H.L., Fairhurst, J., Torres, M., Rafique, A., et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates. J. Infect. Dis., 2018, 10.1093/infdis/jiy285.
57. Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M., Prettenhofer, P., Weiss, R., Dubourg, V., et al. Scikit-learn: Machine Learning in Python. J. Mach. Learn. Res. 12 (2011), 2825–2830.
58. Perez, L.G., Martinez, D.R., deCamp, A.C., Pinter, A., Berman, P.W., Francis, D., Sinangil, F., Lee, C., Greene, K., Gao, H., et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLoS ONE, 12, 2017, e0180720.
59. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004), 1605–1612.
60. Pushko, P., Bray, M., Ludwig, G.V., Parker, M., Schmaljohn, A., Sanchez, A., Jahrling, P.B., Smith, J.F., Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19 (2000), 142–153.
61. Qiu, X., Alimonti, J.B., Melito, P.L., Fernando, L., Ströher, U., Jones, S.M., Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 141 (2011), 218–227.
62. Qiu, X., Fernando, L., Melito, P.L., Audet, J., Feldmann, H., Kobinger, G., Alimonti, J.B., Jones, S.M., Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis., 6, 2012, e1575.
63. Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
64. Regules, J.A., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Hu, Z., Muñoz, P., Moon, J.E., Ruck, R.C., Bennett, J.W., et al., rVSVΔG-ZEBOV-GP Study Group. A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N. Engl. J. Med. 376 (2017), 330–341.
65. Sanchez, A., Trappier, S.G., Mahy, B.W., Peters, C.J., Nichol, S.T., The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. USA 93 (1996), 3602–3607.
66. Sanchez, A., Yang, Z.Y., Xu, L., Nabel, G.J., Crews, T., Peters, C.J., Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. J. Virol. 72 (1998), 6442–6447.
67. Santra, S., Tomaras, G.D., Warrier, R., Nicely, N.I., Liao, H.-X., Pollara, J., Liu, P., Alam, S.M., Zhang, R., Cocklin, S.L., et al. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog., 11, 2015, e1005042.
68. Saphire, E.O., Dye, J.M., Kobinger, G.P., Zeitlin, L., Chandran, K., Garry, R.F., How to turn competitors into collaborators. Nature 541 (2017), 283–285.
69. Schmaljohn, A.L., Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts. Curr. HIV Res. 11 (2013), 345–353.
70. Schmaljohn, A., Lewis, G.K., Cell-targeting antibodies in immunity to Ebola. Pathog. Dis., 74, 2016, ftw021.
71. Schornberg, K., Matsuyama, S., Kabsch, K., Delos, S., Bouton, A., White, J., Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol. 80 (2006), 4174–4178.
72. Shedlock, D.J., Bailey, M.A., Popernack, P.M., Cunningham, J.M., Burton, D.R., Sullivan, N.J., Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401 (2010), 228–235.
73. Shields, R.L., Lai, J., Keck, R., O'Connell, L.Y., Hong, K., Meng, Y.G., Weikert, S.H.A., Presta, L.G., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002), 26733–26740.
74. Smith, K., Garman, L., Wrammert, J., Zheng, N.-Y., Capra, J.D., Ahmed, R., Wilson, P.C., Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4 (2009), 372–384.
75. Sullivan, N.J., Martin, J.E., Graham, B.S., Nabel, G.J., Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7 (2009), 393–400.
76. Takada, A., Feldmann, H., Stroeher, U., Bray, M., Watanabe, S., Ito, H., McGregor, M., Kawaoka, Y., Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J. Virol. 77 (2003), 1069–1074.
77. Volchkov, V.E., Becker, S., Volchkova, V.A., Ternovoj, V.A., Kotov, A.N., Netesov, S.V., Klenk, H.D., GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214 (1995), 421–430.
78. Waggoner, S.N., Reighard, S.D., Gyurova, I.E., Cranert, S.A., Mahl, S.E., Karmele, E.P., McNally, J.P., Moran, M.T., Brooks, T.R., Yaqoob, F., Rydyznski, C.E., Roles of natural killer cells in antiviral immunity. Curr. Opin. Virol. 16 (2016), 15–23.
79. Wec, A.Z., Nyakatura, E.K., Herbert, A.S., Howell, K.A., Holtsberg, F.W., Bakken, R.R., Mittler, E., Christin, J.R., Shulenin, S., Jangra, R.K., et al. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses. Science 354 (2016), 350–354.
80. Wilkinson, D.E., Page, M., Mattiuzzo, G., Hassall, M., Dougall, T., Rigsby, P., Stone, L., Minor, P., Comparison of platform technologies for assaying antibody to Ebola virus. Vaccine 35 (2017), 1347–1352.
81. Wilson, J.A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A.L., Hart, M.K., Epitopes involved in antibody-mediated protection from Ebola virus. Science 287 (2000), 1664–1666.
82. Wong, A.C., Sandesara, R.G., Mulherkar, N., Whelan, S.P., Chandran, K., A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J. Virol. 84 (2010), 163–175.
83. Wong, G., Richardson, J.S., Pillet, S., Patel, A., Qiu, X., Alimonti, J., Hogan, J., Zhang, Y., Takada, A., Feldmann, H., Kobinger, G.P., Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci. Transl. Med., 4, 2012, 158ra146.
84. Zhao, X., Howell, K.A., He, S., Brannan, J.M., Wec, A.Z., Davidson, E., Turner, H.L., Chiang, C.-I., Lei, L., Fels, J.M., et al. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 169 (2017), 891–904.e15.
85. Zou, H., Hastie, T., Regularization and variable selection via the elastic net. J. R. Stat. Soc. Series B Stat. Methodol. 67 (2005), 301–320.